Brian is the CEO of TheracosBio, a privately held company based in Massachusetts. In July 2023, TheracosBio launched its first product, Brenzavvy, a highly specific SGLT-2 inhibitor for the treatment of Type 2 Diabetes.
Prior to joining TheracosBio, Brian served in both advisory and managerial capacities in private and public life sciences companies. He practiced law for over 15 years with Faber, Daeufer & Itrato PC, a boutique law firm supporting the needs of biotech and life science companies, and has assisted early stage drug development companies with CMC and supply chain matters, quality management systems and laboratory space planning. In 2017, he co-founded IncreVet, Inc., an innovative veterinary drug development company that gained FDA approval for an oral medication that was the first non-insulin treatment approved for the management of feline diabetes. IncreVet was acquired by TheracosBio in early 2022.
Brian attended Boston College, the George Washington University Law School and the London School of Economics. He lives in Exeter, NH with his wife and three children.
- Primary/Complementary Interactive Styles: Mastermind/Expert
- Interactive Combination: The Eccentric
- In a film, he’d be played by: Christopher Walken
- Common Leadership Characteristic: An individual with the ability to combine big ideas with specific details to make the unreal, real
